Novavax reports $68M Q3 revenue, raises 2026 revenue forecast, and advances vaccine trials with Sanofi.

Novavax reported $68 million in revenue for Q3 2026, slightly down from last year, but raised its full-year 2026 revenue forecast to $400 million at the midpoint. The company earned a $125 million milestone from Sanofi's launch of a Phase 3 influenza-COVID-19 vaccine trial in Europe and expects a U.S. trial in 2027. Novavax is also advancing its C. difficile vaccine program toward clinical trials and exploring oncology applications. Cost reductions and strong partnerships support its strategy for diversified growth and global health impact.

Following Novavax's Q3 2026 report and updated revenue forecast, its stock price on Pluang rose 5.31% to USD 11.21 as of Nov 05, 2026 20:12 WIB. Meanwhile, Sanofi shares showed a modest gain of 0.15%, trading at USD 47.54. Novavax's market cap stands at $1.76 billion, reflecting investor interest in its vaccine pipeline and partnerships.